Osteoporosis: mechanism, molecular target and current status on drug development
Osteoporosis is a pathological loss of bone mass due to an imbalance in bone remodeling
where osteoclast-mediated bone resorption exceeds osteoblast-mediated bone formation …
where osteoclast-mediated bone resorption exceeds osteoblast-mediated bone formation …
Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women
A guidance on the assessment and treatment of postmenopausal women at risk from
fractures due to osteoporosis was recently published in Osteoporosis International as a joint …
fractures due to osteoporosis was recently published in Osteoporosis International as a joint …
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis
Patients living with osteoporosis are projected to increase dramatically in the next decade.
Alongside the forecasted increased societal and economic burden, we will live a crisis of …
Alongside the forecasted increased societal and economic burden, we will live a crisis of …
Treating osteoporosis to prevent fractures: current concepts and future developments
M Lorentzon - Journal of internal medicine, 2019 - Wiley Online Library
Antiresorptive drugs, such as the bisphosphonates and the RANKL inhibitor denosumab,
are currently the most widely used osteoporosis medications. These drugs increase bone …
are currently the most widely used osteoporosis medications. These drugs increase bone …
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
ContextThe optimal duration of treatment of women with postmenopausal osteoporosis is
uncertain. ObjectiveTo compare the effects of discontinuing alendronate treatment after 5 …
uncertain. ObjectiveTo compare the effects of discontinuing alendronate treatment after 5 …
[HTML][HTML] American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis …
NB Watts, JP Bilezikian, PM Camacho… - … : official journal of the …, 2010 - ncbi.nlm.nih.gov
Osteoporosis is a growing major public health problem with impact that crosses medical,
social, and economic lines. These guidelines have been developed by the American …
social, and economic lines. These guidelines have been developed by the American …
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Guidance is provided in a European setting on the assessment and treatment of
postmenopausal women with or at risk from osteoporosis. Introduction The European …
postmenopausal women with or at risk from osteoporosis. Introduction The European …
Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis
F Cosman, JW Nieves… - Journal of bone and …, 2017 - academic.oup.com
The effects of anabolic medications (teriparatide [TPTD] and parathyroid hormone [PTH])
differ in patients who have received recent treatment with potent antiresorptives. This …
differ in patients who have received recent treatment with potent antiresorptives. This …
Observations following discontinuation of long-term denosumab therapy
MR McClung, RB Wagman, PD Miller, A Wang… - Osteoporosis …, 2017 - Springer
Stopping denosumab after 8 years of continued treatment was associated with bone loss
during a 1-year observation study in patients who were not prescribed osteoporosis …
during a 1-year observation study in patients who were not prescribed osteoporosis …
[PDF][PDF] Osteoporosis: review of etiology, mechanisms, and approach to management in the aging population
S Khandelwal, NE Lane - Endocrinology and metabolism clinics of North …, 2023 - Elsevier
Osteoporosis is the most common metabolic bone disease. With special respect to in the
older population, it is very common, not only due to changes in lifestyle and diet but as a …
older population, it is very common, not only due to changes in lifestyle and diet but as a …